Premature atherosclerosis in systemic lupus erythematosus

Norman Todd Ilowite

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Premature atherosclerosis is a recognized complication of systemic lupus erythematosus (SLE). Since life expectancy in SLE is improving, premature atherosclerosis is emerging as an ever more important clinical issue. Atherosclerosis begins in the pediatric age group, and interventions directed at prevention should begin in childhood as well. Possible etiologies include dyslipoproteinemia (DL) from the underlying chronic inflammatory disease or from corticosteroid therapy, hypercoagulation due to antiphospholipid antibodies or nephrotic syndrome, vasculitis, and hypertension. A relationship between DL and presence of anticardiolipin antibodies (aCL) has been reported. Dietary therapy is helpful, but many patients continue to have significant DL after both dietary modification and fish oil supplementation. Lipid lowering drugs may be indicated in this subgroup. Potential mechanisms of the DL are discussed. Other strategies to prevent atherosclerosis and its complications are reviewed.

Original languageEnglish (US)
Pages (from-to)15-19
Number of pages5
JournalJournal of Rheumatology
Volume27
Issue numberSUPPL. 58
StatePublished - 2000

Fingerprint

Dyslipidemias
Systemic Lupus Erythematosus
Atherosclerosis
Unsaturated Dietary Fats
Diet Therapy
Anticardiolipin Antibodies
Antiphospholipid Syndrome
Fish Oils
Nephrotic Syndrome
Vasculitis
Life Expectancy
Adrenal Cortex Hormones
Chronic Disease
Age Groups
Pediatrics
Hypertension
Lipids
Therapeutics
Pharmaceutical Preparations

Keywords

  • Atherosclerosis
  • Childhood
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Premature atherosclerosis in systemic lupus erythematosus. / Ilowite, Norman Todd.

In: Journal of Rheumatology, Vol. 27, No. SUPPL. 58, 2000, p. 15-19.

Research output: Contribution to journalArticle

Ilowite, NT 2000, 'Premature atherosclerosis in systemic lupus erythematosus', Journal of Rheumatology, vol. 27, no. SUPPL. 58, pp. 15-19.
Ilowite, Norman Todd. / Premature atherosclerosis in systemic lupus erythematosus. In: Journal of Rheumatology. 2000 ; Vol. 27, No. SUPPL. 58. pp. 15-19.
@article{922ac2494b6e403d87162662f7de5800,
title = "Premature atherosclerosis in systemic lupus erythematosus",
abstract = "Premature atherosclerosis is a recognized complication of systemic lupus erythematosus (SLE). Since life expectancy in SLE is improving, premature atherosclerosis is emerging as an ever more important clinical issue. Atherosclerosis begins in the pediatric age group, and interventions directed at prevention should begin in childhood as well. Possible etiologies include dyslipoproteinemia (DL) from the underlying chronic inflammatory disease or from corticosteroid therapy, hypercoagulation due to antiphospholipid antibodies or nephrotic syndrome, vasculitis, and hypertension. A relationship between DL and presence of anticardiolipin antibodies (aCL) has been reported. Dietary therapy is helpful, but many patients continue to have significant DL after both dietary modification and fish oil supplementation. Lipid lowering drugs may be indicated in this subgroup. Potential mechanisms of the DL are discussed. Other strategies to prevent atherosclerosis and its complications are reviewed.",
keywords = "Atherosclerosis, Childhood, Systemic lupus erythematosus",
author = "Ilowite, {Norman Todd}",
year = "2000",
language = "English (US)",
volume = "27",
pages = "15--19",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "SUPPL. 58",

}

TY - JOUR

T1 - Premature atherosclerosis in systemic lupus erythematosus

AU - Ilowite, Norman Todd

PY - 2000

Y1 - 2000

N2 - Premature atherosclerosis is a recognized complication of systemic lupus erythematosus (SLE). Since life expectancy in SLE is improving, premature atherosclerosis is emerging as an ever more important clinical issue. Atherosclerosis begins in the pediatric age group, and interventions directed at prevention should begin in childhood as well. Possible etiologies include dyslipoproteinemia (DL) from the underlying chronic inflammatory disease or from corticosteroid therapy, hypercoagulation due to antiphospholipid antibodies or nephrotic syndrome, vasculitis, and hypertension. A relationship between DL and presence of anticardiolipin antibodies (aCL) has been reported. Dietary therapy is helpful, but many patients continue to have significant DL after both dietary modification and fish oil supplementation. Lipid lowering drugs may be indicated in this subgroup. Potential mechanisms of the DL are discussed. Other strategies to prevent atherosclerosis and its complications are reviewed.

AB - Premature atherosclerosis is a recognized complication of systemic lupus erythematosus (SLE). Since life expectancy in SLE is improving, premature atherosclerosis is emerging as an ever more important clinical issue. Atherosclerosis begins in the pediatric age group, and interventions directed at prevention should begin in childhood as well. Possible etiologies include dyslipoproteinemia (DL) from the underlying chronic inflammatory disease or from corticosteroid therapy, hypercoagulation due to antiphospholipid antibodies or nephrotic syndrome, vasculitis, and hypertension. A relationship between DL and presence of anticardiolipin antibodies (aCL) has been reported. Dietary therapy is helpful, but many patients continue to have significant DL after both dietary modification and fish oil supplementation. Lipid lowering drugs may be indicated in this subgroup. Potential mechanisms of the DL are discussed. Other strategies to prevent atherosclerosis and its complications are reviewed.

KW - Atherosclerosis

KW - Childhood

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=0034038341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034038341&partnerID=8YFLogxK

M3 - Article

C2 - 10782851

AN - SCOPUS:0034038341

VL - 27

SP - 15

EP - 19

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - SUPPL. 58

ER -